Study summary

A gentler CAR T-cell therapy put 77% of adults with relapsed ALL into remission

FELIX trial (obe-cel) · 153 enrolled, phase 1b-2 · Published November 2024, New England Journal of Medicine; FDA approved November 2024

77%overall remission rate

What was tested

Obecabtagene autoleucel (obe-cel), a CAR T-cell therapy designed to cause less severe immune reactions, for adults with relapsed or refractory B-cell ALL.

What they found

Overall remission was 77%, with complete remission in 55%.
Severe cytokine release syndrome occurred in only 2.4% and severe neurotoxicity in 7.1%.
Median overall survival was 15.6 months.

What it means

The first CAR T-cell therapy approved specifically for adults with ALL with a safety profile designed for older patients.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.